Class / Patent application number | Description | Number of patent applications / Date published |
424195110 | Conjugate or complex includes hormone or other secreted growth regulatory factor, differentiation factor, intercellular mediator, or fragment thereof | 13 |
20080286297 | Chimeric Carrier Molecules for the Production of Mucosal Vaccines - The invention relates to a protein complex for the delivery of an antigen to and across mucosal surfaces and the production of said complex in a host cell, such as a plant. Provided is a protein complex comprising at least two, preferably identical, subunits wherein at least one subunit is unaltered and at least one subunit is fused to a first molecule of interest and wherein the protein complex is able to interact with a cell surface receptor via said subunits. Also provided is a method for producing a protein complex according to the invention, comprising a) providing a host cell with a nucleotide sequence encoding an unaltered subunit and a nucleotide sequence encoding a molecule of interest, wherein at least one molecule of interest is fused to a subunit; b) culturing said host cell thereby allowing expression of said nucleotide sequences and allowing for assembly of the protein complex; c) isolating the complex; d) determining the binding of the complex to a cell surface receptor or to a molecule which mimics a cell surface receptor | 11-20-2008 |
20100196412 | HOMOGENEOUS VACCINE COMPOSITION FOR THE TUMOR TREATMENT AND ITS OBTAINING METHOD - The present invention relates to the biotechnological field and particularly to the human health. More particularly, the present invention relates to a vaccine composition for therapeutic use in cancer patients. | 08-05-2010 |
20110081371 | Angiotensin peptide-carrier conjugates and uses thereof - The present invention provides conjugates of peptide derivatives of the mammalian peptide hormones angiotensinogen, angiotensin I and angiotensin II, presented in a repetitive scaffold by coupling the peptide derivatives to a carrier, particularly a virus-like particle (VLP). The invention also provides methods of producing such conjugates, and immunotherapeutic uses of the resulting immunogen conjugates for the therapy and prophylaxis of conditions associated with the renin-activated angiotensin system. | 04-07-2011 |
20110200633 | Cytomegalovirus Surface Protein Complex for Use in Vaccines and as a Drug Target - Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection. | 08-18-2011 |
20110256169 | NOVEL POLYPEPTIDES RELATED TO B-TYPE NATRIURETIC PEPTIDES AND METHODS OF THEIR IDENTIFICATION AND USE - The invention provides novel fragments of proBNP and NTproBNP, particularly useful in prognosing or diagnosing acute heart failure, chronic heart failure or sepsis. | 10-20-2011 |
20120251566 | SAPONIN ADJUVANT COMPOSITIONS AND METHODS RELATING THERETO - An adjuvant composition which comprises an anionic macromolecule component particularly an ionic polysaccharide such as DEAE-dextran, and a saponin component, particularly an immunostimulating complex component. Immunogenic compositions comprising an immunogen and this adjuvant composition are also disclosed together with methods of use thereof. | 10-04-2012 |
20130011430 | HUMAN CHORIONIC GONADOTROPIN (hCG) BASED VACCINE FOR PREVENTION AND TREATMENT OF CANCER - The present invention is directed to a vaccine and a pharmaceutical composition comprising hCG and | 01-10-2013 |
20130039940 | Homogenous Vaccine Composition Comprising a Conjugate of EGF and P64K for the Treatment of Tumors - A vaccine composition for therapeutic use thereof on cancer patients includes a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and a combining protein P64k for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. The preferred conjugate surprisingly increases the immunogenic activity causing significant increases in the anti-EGF antibody titers in humans, and provides a vaccine preparation with more than one type of effective dose presentation which enables the immunization dose per patient to be increased, but without involving an increase in immunization frequency and/or the number of immunization sites. | 02-14-2013 |
20130149332 | Methods for Enhanced Somatostatin Immunogenicity in the Treatment of Obesity - Compositions and methods are provided for treatment growth hormone and/or insulin-like growth factor 1 deficiency in a patient in need of such treatment. Compositions and methods include novel vaccines that provide immunogenicity for somatostatin and result in the increased release of endogenously produced growth hormone and/or insulin-like growth factor 1. | 06-13-2013 |
20130209503 | METHOD FOR STABILIZATION OF BIOLOGICAL MOLECULES - Thermostable polysaccharide based lyophilized vaccines are disclosed, particularly polysaccharide-protein conjugate vaccines and methods for preparation thereof. In an exemplary embodiment, a stabilized vaccine composition consists essentially of at least one polysaccharide-protein conjugate, at least one amorphous excipient, and a buffer component. | 08-15-2013 |
20130259892 | STRONGLY INACTIVATED AND STILL HIGHLY IMMUNOGENIC VACCINE AND PROCESS OF MANUFACTURING THEREOF - An immunogenic product includes TNFα coupled with KLH, wherein the TNFα is strongly inactivated, which means that the product shows less than 30% of cytolytic activity and/or an inactivation factor of more than 15000, in the conditions of TEST A. An emulsion and a vaccine including the product and methods for preparing the immunogenic product are also described. | 10-03-2013 |
20130344102 | FORMULATION - The present invention relates to a CRH formulation having improved stability/efficacy. The improved CRH formulation is particularly suitable for treatment of various disorders. The invention also relates to a method of producing the CRH formulation, and to methods of treatment using said CRH formulation. | 12-26-2013 |
20140017274 | METHOD FOR THE PRODUCTION OF PROTEIN COMPLEXES AND VACCINE COMPOSITIONS COMPRISING THE SAME - The present invention relates to methods for the production of heat shock protein complexes for use in vaccine compositions. In particular, there is provided a method for increasing the level and immunogenicity of heat shock protein complexes produced in cells by subjecting the cells to specific stress inducing stimuli. The invention further extends to the use of heat shock protein complexes produced according to the methods of the invention in the preparation of vaccine compositions for the prevention and treatment of infectious diseases and cancerous conditions. | 01-16-2014 |